NCT00003759View on ClinicalTrials.gov

AD 32 With or Without BCG After Surgery in Treating Patients With Newly Diagnosed or Recurrent Superficial Bladder Cancer

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

November 30, 1998

Study Completion Date

November 30, 2002

Conditions
Bladder Cancer
Interventions
BIOLOGICAL

BCG vaccine

DRUG

valrubicin

PROCEDURE

conventional surgery

Trial Locations (1)

77030-4009

University of Texas - MD Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
lead

Anthra Pharmaceuticals

INDUSTRY

NCT00003759 - AD 32 With or Without BCG After Surgery in Treating Patients With Newly Diagnosed or Recurrent Superficial Bladder Cancer | Biotech Hunter | Biotech Hunter